First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically ...
Jun 7, 2023
0
3
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study ...
May 29, 2019
0
14
With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern. It has often been assumed that drug resistance is due to the presence or development ...
May 15, 2019
0
14
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer ...
Dec 6, 2020
0
5
Researchers at Karolinska Institutet have investigated the use of low dose venetoclax, an experimental drug, for the treatment of the heterogeneous cancer disease multiple myeloma in patients who had relapsed on standard ...
May 19, 2021
0
27
Researchers in Finland have discovered a drug combination that collaborates with the cancer cell oncoprotein MYC, which, in large quantities, causes self-destruction of the cancer cells. When this combination is enhanced ...
Feb 6, 2019
0
6
Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML ...
Dec 13, 2021
0
1
Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong ...
May 9, 2024
0
0
New research from the Royal College of Surgeons in Ireland has found that venetoclax, a medication currently approved for leukemia, provides benefits for patients with multiple myeloma when used in combination with another ...
Mar 25, 2024
0
3
A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.
Mar 25, 2024
0
0
